» Articles » PMID: 24409050

Current Management of Fecal Incontinence: Choosing Amongst Treatment Options to Optimize Outcomes

Overview
Specialty Gastroenterology
Date 2014 Jan 11
PMID 24409050
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The severity of fecal incontinence widely varies and can have dramatic devastating impacts on a person's life. Fecal incontinence is common, though it is often under-reported by patients. In addition to standard treatment options, new treatments have been developed during the past decade to attempt to effectively treat fecal incontinence with minimal morbidity. Non-operative treatments include dietary modifications, medications, and biofeedback therapy. Currently used surgical treatments include repair (sphincteroplasty), stimulation (sacral nerve stimulation or posterior tibial nerve stimulation), replacement (artificial bowel sphincter or muscle transposition) and diversion (stoma formation). Newer augmentation treatments such as radiofrequency energy delivery and injectable materials, are minimally invasive tools that may be good options before proceeding to surgery in some patients with mild fecal incontinence. In general, more invasive surgical treatments are now reserved for moderate to severe fecal incontinence. Functional and quality of life related outcomes, as well as potential complications of the treatment must be considered and the treatment of fecal incontinence must be individualized to the patient. General indications, techniques, and outcomes profiles for the various treatments of fecal incontinence are discussed in detail. Choosing the most effective treatment for the individual patient is essential to achieve optimal outcomes in the treatment of fecal incontinence.

Citing Articles

Role of Hypoxic Secretome from Mesenchymal Stem Cells in Enhancing Tissue Repair: Regulatory Effects on HIF-1α, VEGF, and Fibroblast in a Sphincterotomy Rat Model.

Lumban Gaol L, Purba A, Diposarosa R, Pratiwi Y J Inflamm Res. 2024; 17:7463-7484.

PMID: 39464333 PMC: 11505569. DOI: 10.2147/JIR.S480061.


Faecal incontinence-a comprehensive review.

Dexter E, Walshaw J, Wynn H, Dimashki S, Leo A, Lindsey I Front Surg. 2024; 11:1340720.

PMID: 38362459 PMC: 10867159. DOI: 10.3389/fsurg.2024.1340720.


Accurate anatomic repair of obstetric anal sphincter damage or rectovaginal fistula aided by prior ultrasonograghy: a cohort study.

Mokoena T, Abdool Z Ann Med Surg (Lond). 2023; 85(6):2319-2323.

PMID: 37363522 PMC: 10289563. DOI: 10.1097/MS9.0000000000000614.


An evaluation of the long-term effectiveness of Gatekeeper™ intersphincteric implants for passive faecal incontinence.

Jabbar S, Camilleri-Brennan J Tech Coloproctol. 2022; 26(7):537-543.

PMID: 35593969 PMC: 9213285. DOI: 10.1007/s10151-022-02630-z.


Stoma reversal in functional bowel disease: managing patient choice.

Han L, Bean A, Emmett C, Plusa S Ann R Coll Surg Engl. 2021; 103(10):745-751.

PMID: 34414788 PMC: 9773920. DOI: 10.1308/rcsann.2021.0087.


References
1.
Hallgren T, Fasth S, Delbro D, Nordgren S, Oresland T, Hulten L . Loperamide improves anal sphincter function and continence after restorative proctocolectomy. Dig Dis Sci. 1994; 39(12):2612-8. DOI: 10.1007/BF02087698. View

2.
Ellison J, Haraway A, Park J . The distal left Malone antegrade continence enema--is it better?. J Urol. 2013; 190(4 Suppl):1529-33. DOI: 10.1016/j.juro.2013.01.092. View

3.
Goetz L, Lowry A . Overlapping sphincteroplasty: is it the standard of care?. Clin Colon Rectal Surg. 2009; 18(1):22-31. PMC: 2780126. DOI: 10.1055/s-2005-864072. View

4.
Hollingshead J, Dudding T, Vaizey C . Sacral nerve stimulation for faecal incontinence: results from a single centre over a 10-year period. Colorectal Dis. 2010; 13(9):1030-4. DOI: 10.1111/j.1463-1318.2010.02383.x. View

5.
Brill S, Margolin D . Sacral nerve stimulation for the treatment of fecal incontinence. Clin Colon Rectal Surg. 2009; 18(1):38-41. PMC: 2780135. DOI: 10.1055/s-2005-864079. View